This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
No peptide vaccine has been licensed for gynecologic oncology as of January 2022.
Why it matters
Understanding the progress of peptide vaccines can lead to improved treatments for gynecologic cancers. This research highlights the need for continued innovation in immunotherapy.
How the study worked
The study is a review of clinical trials registered on ClinicalTrials.gov up to January 1, 2022.
What this study cannot tell us
The review does not provide new clinical trial data or outcomes, focusing instead on existing studies.
Read the original research
The progress of peptide vaccine clinical trials in gynecologic oncology.
Human vaccines & immunotherapeutics, 18(5), 2062982
Citation
Tang, Mi; Cai, Jiang-Hui; Diao, Hao-Yang; Guo, Wen-Mei; Yang, Xiao; Xing, ShaSha. (2022). The progress of peptide vaccine clinical trials in gynecologic oncology.. Human vaccines & immunotherapeutics, 18(5), 2062982. https://doi.org/10.1080/21645515.2022.2062982